Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is a Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the ARB class and is used to manage conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes. - Proteinuria associated with diabetes: reduces urinary protein excretion, indicating renal protection.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nasal congestion: blocked or runny nose. - Back pain: discomfort in the lumbar region.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may compromise breathing. - Severe hyperkalaemia: markedly elevated blood potassium levels. - Acute renal impairment: sudden decline in kidney function. - Hepatic injury: abnormal liver enzyme elevations. - Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should assess patient-specific factors and monitor relevant parameters. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR regularly. - Serum potassium evaluation: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Hepatic impairment caution: adjust use in patients with liver disease. - Pregnancy avoidance: discontinue if pregnancy is confirmed or planned. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines; careful review is required. Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase renal risk. - ACE inhibitors or other ARBs: concurrent therapy may cause excessive potassium rise and kidney injury. - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalaemia. Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect and affect renal function. - Lithium: irbesartan can increase lithium concentrations, requiring serum level monitoring.